公开(公告)号：US20210105980A1

公开(公告)日：2021-04-15

申请号：US17050199

申请日：2019-04-25

Applicant: Hoffmann-La Roche Inc. ,  HOFFMANN-LA ROCHE INC.

Inventor： Przemek IDZIASZEK ,  Antoni OPOLSKI ,  Jacek ZIEMSKI ,  Bartosz BINIAS

IPC: A01K29/00 ,  A01K11/00

Abstract: A method of tracking an animal (4) in a population of animals (4) comprises: applying a visual identifier (41) to the animal (4); associating reference identifier data of the visual identifier (41) to animal data of the animal (4); capturing a digital image of the visual identifier (41) applied to the animal (4); recognizing the visual identifier (41) by digitally processing the captured digital image; and identifying the animal (4) upon recognition of the visual identifier (41).

公开(公告)号：US20180312546A1

公开(公告)日：2018-11-01

申请号：US15981316

申请日：2018-05-16

Applicant: Drexel University ,  Baruch S. Blumberg Institute ,  Hoffmann-La Roche Inc.

Inventor： Haitao Guo ,  Dawei Cai ,  Andrea Cuconati ,  Changhua Ji

IPC: C07K14/005 ,  G01N33/50

CPC classification number: C07K14/005 ,  C07K2319/40 ,  C07K2319/42 ,  C12N2730/10122 ,  C12N2730/10151 ,  C12N2830/006 ,  G01N33/502 ,  G01N2333/02

Abstract: The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

公开(公告)号：US20250066378A1

公开(公告)日：2025-02-27

申请号：US18936608

申请日：2024-11-04

Applicant: Hoffmann-La Roche Inc.

Inventor： Valerie Runtz-Schmitt ,  Patrick Schnider ,  Cosimo Dolente ,  Bernhard Fasching

IPC: C07D491/107 ,  C07D491/10 ,  C07D491/12 ,  C07D491/20 ,  C07D498/10 ,  C07D519/00

Abstract: The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.

公开(公告)号：US20250059270A1

公开(公告)日：2025-02-20

申请号：US18662445

申请日：2024-05-13

Applicant: Hoffmann-La Roche, Inc.

Inventor： Michael March Schmidt ,  Alison Tisdale ,  Eric Steven Furfine ,  Grigorios Zarbis-Papastoitsis

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61P3/10 ,  A61P27/02 ,  C07K16/40

Abstract: Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6 related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

公开(公告)号：US20250051456A1

公开(公告)日：2025-02-13

申请号：US18933578

申请日：2024-10-31

Applicant: Hoffmann-La Roche Inc.

Inventor： Stefan DENGL ,  Sebastian FENN ,  Jens FISCHER ,  Andreas HINZ ,  Claudia KIRSTENPFAD ,  Stefan KLOSTERMANN ,  Joerg MOELLEKEN ,  Georg TIEFENTHALER ,  Sabine HOVES ,  Alexander BUJOTZEK ,  Meher MAJETY

IPC: C07K16/28 ,  G01N33/68

Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.

公开(公告)号：US12209091B2

公开(公告)日：2025-01-28

申请号：US17105060

申请日：2020-11-25

Applicant: Hoffmann-La Roche Inc.

Inventor： Martin Duplessis ,  Annick Goergler ,  Georg Jaeschke ,  Buelent Kocer ,  Bernd Kuhn ,  Kiel Lazarski ,  Yanke Liang ,  Yvonne Alice Nagel ,  Ulrike Obst Sander ,  Antonio Ricci ,  Daniel Rueher ,  Sandra Steiner

IPC: C07D487/04 ,  A61K9/00 ,  A61K9/02 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38

Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

公开(公告)号：US12203943B2

公开(公告)日：2025-01-21

申请号：US17724406

申请日：2022-04-19

Applicant: Hoffmann La-Roche Inc. ,  INSERM (Institut National de la Santé et de la Recherche Médicale)

Inventor： Melanie Broueilh ,  Mordi Muorah ,  Fabiola Terzi

IPC: G01N33/68 ,  G01N33/74

Abstract: The present invention relates to methods for the prediction of the progression of chronic kidney disease in a patient. More particularly, the invention relates to the early prediction of the fast progression of chronic kidney disease using specific biomarker signatures in urine sample of patients.

公开(公告)号：US20250018032A1

公开(公告)日：2025-01-16

申请号：US18893603

申请日：2024-09-23

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Mark C. Benyunes ,  Graham Alexander Ross

IPC: A61K39/395 ,  A61K9/00 ,  A61K31/337 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/32

Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

公开(公告)号：US12195413B2

公开(公告)日：2025-01-14

申请号：US17338643

申请日：2021-06-03

Applicant: Hoffmann-La Roche Inc.

Inventor： Georg Jaeschke ,  Lothar Lindemann ,  Antonio Ricci ,  Eric Vieira

IPC: C07C11/22 ,  A61K31/4166 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/4439 ,  A61P1/00 ,  A61P1/04 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  C07D213/81 ,  C07D401/04 ,  C07D403/04

Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

公开(公告)号：US20250011300A1

公开(公告)日：2025-01-09

申请号：US18704018

申请日：2022-10-24

Applicant: Hoffmann-La Roche Inc.

Inventor： Fabian Dey ,  Xiao Ding ,  Houguang Shi ,  Xuefei Tan ,  Jun Wu ,  Jiamin Zheng ,  Mingwei Zhou

IPC: C07D401/12 ,  A61K31/635 ,  A61P31/04 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D493/08 ,  C07D498/04 ,  C07D498/10

Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3, Y, Q1, Q2, Q3, Q4 and Q5 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.